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ABSTRACT
Introduction Metabolic disorder and high blood pressure 
are common complications globally, and speciically 
among people living with HIV (PLHIV). Diabetes, metabolic 
syndrome and hypertension are major risk factors for 
cardiovascular diseases and their related complications. 
However, the burden of metabolic syndrome, discrete or 
comorbid diabetes and hypertension in PLHIV compared 
with HIV-negative population has not been quantiied. 
This review and meta-analysis aims to compare and 
analyse the prevalence of these trio conditions between 
HIV-negative and HIV-positive populations in sub-Saharan 
Africa (SSA).
Methods and analysis The Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis statement 
guides the methods for this study. Eligibility criteria 
will be published original articles (English and French 
language) from SSA that present the prevalence of 
metabolic syndrome, discrete and/or comorbid diabetes, 
and hypertension comparisons between PLHIV and HIV-
negative populations. The following databases will be 
searched from January 1990 to February 2017: PubMed/
Medline, EBSCOhost, Web of Science, Google Scholar, 
Scopus, African Index Medicus and Cochrane Database of 
Systematic Reviews. Eligibility screening and data extraction 
will be conducted independently by two reviewers, and 
disagreements resolved by an independent reviewer. 
Methodological quality and risk of bias will be assessed 
for individual included studies, while meta-analysis will be 
used to estimate study outcomes prevalence according to 
subgroups. Sensitivity analysis will also be performed to 
further test the robustness of the indings.
Ethics and dissemination This proposed study does not 
require ethical approval. The results will be published as a 
scientiic article in a peer-reviewed journal, and presented 
at conferences and to relevant health agencies.
Trial registration number PROSPERO registration 
number (CRD42016045727).
INTRODUCTION/RATIONALE
The epidemiological transition model devel-
oped by Omran argued that infectious and 
parasitic diseases will decrease, while chronic 
and ageing-related conditions and diseases 
will increase, these changes being driven by 
social factors and lifestyles.1 2 The generali-
sation of Omran’s model to low-income and 
middle-income countries (LMICs) is not 
applicable due to the increased incidence of 
chronic diseases, an ageing population with 
related health conditions and a resurgence of 
infectious diseases among this population.2 3 
Frenk et al3 envisioned the protracted epide-
miological transition model as being able 
to describe the health inequality, morbidity 
and mortality by social class, this being 
applicable to LMICs that are faced with 
prolonged periods of both infectious and 
chronic diseases.4 Sub-Saharan Africa (SSA) 
is also undergoing a demographic transition, 
with increased population size and growth, 
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Strengths and limitations of this study
 Ź Understanding the differences in the burden of 
metabolic syndrome (and its subcomponents), 
diabetes and hypertension between HIV-positive and 
HIV-negative populations.
 Ź This review contributes to informing public health 
actions needed for non-communicable disease 
(NCD) comorbidities and population health.
 Ź Stringent adherence to the  Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis 
Statement guidelines.
 Ź Inclusion of non-English-language (French) 
published studies and literature to increase the 
representativeness of the indings in the region.
 Ź A limitation is the lack of single deinition criteria 
of metabolic syndrome over the study period; thus, 
hypertension and diabetes are inclusive of the 
subcomponents.
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changing age structures, inequality, urbanisation and 
rural exodus.5 In addition, these countries now have 
the highest prevalence of HIV/AIDS, with many people 
being on antiretroviral treatment.6 Within this context, 
the prevalence of non-communicable diseases (trio) is 
increasing and is projected to exceed that of commu-
nicable diseases by 2030,7 due to epidemiological and 
demographic transitions.8
The leading non-communicable conditions are cardio-
vascular diseases (CVD) and diabetes, with hypertension 
being a major risk factor.8 Diabetes is a metabolic condition 
that affects mainly adults around the world, specifically 
type 2, which is the most prevalent, accounting for approx-
imately 95% of all cases.9 10 Diabetes and hypertension are 
also major causes of increased morbidity, mortality and 
other health complications globally.11 12 The global prev-
alence of hypertension is 20%–50%,13 while estimates 
suggest that diabetes will affect approximately 642 million 
people by 2040, mostly among adults of age 20 years and 
above.13–16 Patients with diabetes have an increased inci-
dence of hypertension and other health risks,10 17 the 
predisposing risk factors being obesity, high carbohy-
drate and sugar diets, physical inactivity and other related 
factors clustering into metabolic dysfunctions.18 19
Metabolic syndrome (Mets) is the clustering of risk 
factors for the development of type 2 diabetes and CVD,20 
which has an increasing prevalence in SSA.21 22 This 
condition and its risk factor represents clinical concept 
used to indicate pre-diabetes and prehypertension.23 Mets 
develops from clustering conditions and the risk factors 
of diabetes, hypertension and CVDs. The relationship 
between Mets, diabetes and hypertension is complex, as 
high glucose intolerance and blood pressure are criteria 
for Mets diagnosis, while diabetes and hypertension are 
discretely health conditions. Nevertheless, there are a 
variety of definitions for Mets, each with criteria that influ-
ence its diagnosis and complexity.9 24 The influence of fat 
redistribution, such as visceral obesity, increased waist:hip 
ratio and adipose tissue, is an established presentation of 
cardiometabolic traits.25 Obesity is a major contributor to 
increased glucose intolerance, high blood pressure and 
lipid disorders that result in metabolic dysfunction.26 
However, not all overweight and obese individuals are 
diabetic, and not all patients with diabetes are overweight 
or obese.25 Abdominal obesity is a consistent marker 
of Mets diagnosis,27 and the prevalence of Mets among 
patients with diabetes and hypertension rises with an 
increasingly ageing population.28
These trio conditions (diabetes, hypertension and Mets) 
are highly prevalent among the HIV-infected population 
as a result of their long-term dependence on antiretro-
viral therapy (ART) regimen,29 30 which has been shown to 
be a contributing factor to developing metabolic compli-
cations, such as lipodystrophy, dyslipidemia and insulin 
resistance.31 32 Modifiable lifestyle risk factors similar to 
the general population are also a major contributing 
factor to increasing metabolic disorders.33 Hypertension is 
a common AIDS-unrelated condition among HIV-positive 
persons, with an estimated prevalence of between 4.7% 
and 54.4% in high-income countries and 8.7%–45.9% in 
LMICs.34 These trio conditions have emerged as one of 
the contributors to non-AIDS-related causes of morbidity 
and mortality globally.35 The causative and predisposing 
factors of developing these conditions are similar among 
all populations, regardless of HIV status, and include 
sociodemographic change, an aged population, globali-
sation, overweight, obesity and sedentary lifestyles.16 36 37 
Globally, non-communicable disease (NCD) comor-
bidities in people living with HIV (PLHIV) is high, and 
while its prevalence is similar to the general population 
that is not infected, those who are infected also have to 
contend with the dual burden of NCD and other infec-
tious diseases.38
Studies have shown that metabolic conditions are more 
common among PLHIV due to the HIV infection itself 
and the ARV regimen; however, these have been done 
mainly in developed countries.39–41 Empirical evidence 
about the differential cardiometabolic traits between 
people infected and uninfected with HIV is limited and 
conflicting, especially for SSA, and a consolidated esti-
mate will assist in assessing the need for monitoring 
and managing metabolic dysfunction in HIV-infected 
populations.42 A narrative systematic review indicated 
the difference in the prevalence of hypertension among 
HIV-positive populations in developed countries to be 
between 4.7% and 54.4%, and ranging between 8.7% and 
45.9% in LMICs.34 However, most of the studies included 
in the review were from developed countries, the focus 
being on PLHIV, with no comparative HIV-negative 
control groups. A review without a meta-analysis on the 
prevalence of Mets among PLHIV reported a 30% mean 
prevalence in Africa.43 With only a few studies being from 
South America, Africa and Asia, the result could be an 
overestimation or underestimation.
Most reviews with or without meta-analysis that have 
explored the prevalence of diabetes, hypertension and/
or Mets have focused on PLHIV, without a comparable 
HIV-negative baseline.42 44–47 Moreover, data comparing 
the burden of NCD among the HIV-positive and HIV-neg-
ative populations (in the same setting) are limited, 
especially in the era of increasing longevity due to 
ART roll-out and the epidemiological transition taking 
place in SSA. The growing burden of chronic diseases 
(including chronic HIV) will further strain the region’s 
weak healthcare infrastructure, resources and services, 
and increase healthcare expenditure in coming years.48 
Understanding the burden of Mets (and its individual 
components) among PLHIV is essential to maintaining 
the gains made against acute HIV morbidity and 
mortality.38 This proposed review therefore attempts to 
unpack this multimorbidity aspect by HIV status, thereby 
increasing the accuracy of burden estimation, which is 
needed for effective healthcare system planning in HIV 
endemic settings.49 50 This study will conduct a systematic 
review and meta-analysis specific to SSA, which bears a 
high dual burden due to a protracted epidemiological 
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transition. The risk of metabolic disorders in HIV-posi-
tive people, compared with HIV-negative populations, is 
an important research priority area,51 as relevant data are 
limited, especially in the era of increasing access to ART 
in SSA. This review will attempt to highlight the unique 
contribution of understanding the burden of Mets (and 
its subcomponents) and discrete or comorbid diabetes 
and hypertension by comparing the prevalence between 
HIV-positive and HIV-negative populations in SSA, which 
has not been explored, to the best of our knowledge.
The aim of this study is to conduct a systematic review 
and meta-analysis of studies documented from 1990 to 
2017 to determine the differential prevalence of Mets, 
discrete and/or comorbid diabetes and hypertension 
between HIV-positive and HIV-negative populations in 
SSA.
Research questions
The proposed review will seek to address the following 
research questions:
1. What is the prevalence of diabetes among adults in 
SSA with and without HIV infection?
2. What is the prevalence of hypertension among adults 
in SSA with and without HIV infection?
3. What is the prevalence of Mets among adults in SSA 
with and without HIV infection?
4. What is the prevalence of comorbid diabetes and 
hypertension among adults in SSA with and without 
HIV infection?
METHODS
Eligibility criteria (inclusion and exclusion)
Inclusion criteria
The review will include studies on the prevalence of 
Mets (and its subcomponents), type 2 diabetes and hyper-
tension discretely or as comorbid conditions, and exclude 
those on other related cardiovascular and non-communi-
cable diseases conditions. The following factors will apply:
1. Study designs: This review and meta-analysis will 
include randomised control trials, cross-sectional, 
case–control and cohort studies that assess the 
prevalence of Mets (and subcomponents), discrete 
and/or comorbid diabetes and hypertension among 
PLHIV and/or HIV-negative populations in SSA. 
Included studies will be those conducted with both or 
any of the study outcomes.
2. Study participants: Adult (age 18 years and older) 
human participants residing in SSA, regardless of 
their ethnic background.
3. Study outcome definition: Outcomes will be 
defined through self-report, use of antihypertensive 
and cholesterol-lowering and antidiabetic drugs. 
The WHO/IDF (International Diabetes Federation) 
recommendation on the definition and diagnosis 
of diabetes mellitus for diabetes will be used.52 The 
seventh report of the Joint National Committee on 
Prevention, Detection, Evaluation and Treatment of 
High Blood Pressure will be used for hypertension 
diagnosis definition.53 The diagnosis criteria for Mets 
will be that of the IDF,54 National Cholesterol 
Education Program-Adult Treatment Panel III 
definition (NCEP ATP III),55 European Group for 
Study of Insulin Resistance56 and WHO criteria.55 
Refer to table 1 for outcome definitions.
4. Time-period: Published and grey literature and 
unpublished data reported between 1 January 1990 
and 28 February 2017 will be included, taking into 
account changes in the definition of diabetes and 
Mets over this period.
5. Study settings: Community or population-based 
settings, health facilities settings within rural and 
urban areas of SSA will be included.
6. Study languages: All studies reported in English 
and French languages within any SSA country will 
be considered. The inclusion of French-language 
articles will increase the precision of combined 
estimates of effect size, study result generalisation and 
applicability,57 and enhance the study coverage and 
robustness across SSA. A French-speaking person will 
assess studies published in French to ensure that the 
content and results are not over-rated or under-rated, 
after which they will be translated into English.
7. HIV status: Studies considering the outcome for 
PLHIVs who are on antiretroviral treatment and/or 
are treatment-naïve will be included, as well as those 
relating to HIV-negative populations.
Exclusion criteria
The following factors will apply:
1. Study design: case series/studies, reviews, 
commentaries and other publications without primary 
data.
2. Study participants: studies conducted among African 
populations residing in other continents.
3. Study outcome definition: studies with no Mets criteria 
or definition, and with different stages of hypertension 
progression will be excluded.
4. Study languages: studies published in languages other 
than English and French.
5. Study outcome results: studies lacking prevalence 
rates and data to compute it after consultation with 
the author. Duplicate publications from the same 
studies will be excluded, while those with outcome 
results published in more than one journal will be 
reviewed as one study, and relevant information will 
be collated comprehensively and authors will be 
contacted to validate data extracted.
Source of information and search strategies
This review will be guided and written by the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
ysis Protocols (PRISMA-P) 2015 statement, as indicated 
in table 2.58 Eligible published articles on the prevalence 
of diabetes, hypertension and/or/with Mets among 
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Table 1 Deinition of review outcomes
Diseases/conditions Deinition
  Diabetes mellitus (WHO/IDF) 2006 Fasting plasma glucose (≥7.0 mmol/L (126 mg/dL)) or 2-hour plasma glucose (≥11.1 mmol/L (200 mg/dL))
  Hypertension or high blood pressure —
JNC 753
Hypertension (high blood pressure) deined as ≥140/90/90 mm Hg, systolic and diastolic pressure
The following are the criteria for diagnosis:
1. Optimal blood pressure — <120/80 mm Hg, systolic and diastolic blood pressure
2. Prehypertension — 120–139/80–89 mm Hg, systolic and diastolic blood pressure
3. Stage 1 hypertension — 140–159/90–99 mm Hg, systolic and diastolic blood pressure
4. Stage 2 hypertension — >160/100 mm Hg, systolic and diastolic blood pressure
  Metabolic syndrome Metabolic syndrome is a constellation of interrelated metabolic risk factors that appear to increase the risk and directly 
promote the development of cardiovascular disease and type 2 diabetes mellitus.75 The diagnostic criteria for identifying 
metabolic syndrome for this study include55 75:
t/$&1"51***DSJUFSJB — Diagnosis of 3 out of 5: abdominal obesity, given as waist circumference (men 102 cm (40 
inches), women 88 cm (35 inches)), triglycerides ≥150 mg/dL, HDL cholesterol (men <40 mg/dL, women <50 mg/dL), blood 
pressure ≥130/≥85 mm Hg, fasting glucose ≥110 mg/dL
t8)0DSJUFSJB%JBHOPTJTPGJOTVMJOSFTJTUBODF	FJUIFSUZQFøEJBCFUFTJNQBJSFEGBTUJOHHMVDPTFJNQBJSFEHMVDPTF
tolerance, normal fasting glucose levels (110 mg/dL) or glucose uptake below the lowest quartile). In addition, diagnosis of 
2 other risk factors is suficient.
"OUJIZQFSUFOTJWFNFEJDBUJPOBOEPSIJHICMPPEQSFTTVSF	öNN)HTZTUPMJDPSøöNN)HEJBTUPMJD

2. Plasma triglycerides ≥150 mg/dL (≥1.7 mmol/L)
3. HDL cholesterol (men 35 mg/dL (0.9 mmol/L), women 39 mg/dL (1.0 mmol/L))
4. Body mass index 30 kg/m2 and/or waist:hip ratio (men >0.9, women >0.85)
5. Urinary albumin excretion rate (≥20 g/min) or albumin:creatinine ratio (≥30 mg/g)
t&(*3DSJUFSJB —"QMBTNBJOTVMJOUIQFSDFOUJMFXJUIBOZSJTLGBDUPSTøXBJTUDJSDVNGFSFODF	NFOöDNXPNFO
≥80 cm), triglyceride (≥150 mg/dL) and/or HDL-C (<39 mg/dL) in men or women, ≥140 mm Hg or on antihypertensive 
medication, impaired glucose tolerance or impaired fasting glucose but not diabetes
t*%'DSJUFSJB —"DFOUSBMPCFTJUZBOEBOZøPSøBEEJUJPOBMSJTLGBDUPSTSBJTFEUSJHMZDFSJEF	öNNPM-	NHE-

reduced HDL-cholesterol (male <1.03 mmol/L (40 mg/dL), women <1.29 mmol/L (50 mg/dL)), raised blood pressure 
(≥130/≥85 mm Hg) or antihypertensive drug, raised fasting plasma glucose (≥5.6 mmol/L (100 mg/dL)) or diagnosed type 
2 diabetes
&(*3ø&VSPQFBO(SPVQGPS4UVEZPG*OTVMJO3FTJTUBODF*%'*OUFSOBUJPOBM%JBCFUFT'FEFSBUJPO+/$+PJOU/BUJPOBM$PNNJUUFFPO1SFWFOUJPO%FUFDUJPO&WBMVBUJPOBOE5SFBUNFOUPG
)JHIø#MPPE1SFTTVSF/$&1"51***/BUJPOBM$IPMFTUFSPM&EVDBUJPO1SPHSBN"EVMU5SFBUNFOU1BOFM***EFýOJUJPOø)%-IJHIEFOTJUZMJQPQSPUFJOø
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Table 2 1SFGFSSFE3FQPSUJOH*UFNTGPS4ZTUFNBUJD3FWJFXTBOE.FUB"OBMZTJT1SPUPDPMTDIFDLMJTU
Section/topic Item # Checklist item
Page no 
reference
Line no. 
reference
"ENJOJTUSBUJWFJOGPSNBUJPO
Title 1 3–5
Identiication 1a Identify the report as a protocol of a systematic review 1 5
Update 1b If the protocol is for an update of a previous systematic review, identify as such Not applicable
3FHJTUSBUJPO 2 *GSFHJTUFSFEQSPWJEFUIFOBNFPGUIFSFHJTUSZ	FH13041&30
BOESFHJTUSBUJPOOVNCFS 2 59
"VUIPST 1 6, 12
Contact 3a 1SPWJEFOBNFJOTUJUVUJPOBMBGýMJBUJPOBOEFNBJMBEESFTTPGBMMQSPUPDPMBVUIPSTQSPWJEFQIZTJDBMNBJMJOH
address of corresponding author
1 6–12
Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review 19 671–681
"NFOENFOUT 4 If protocol represents an amendment of a previously completed or published protocol, identify as such and 
MJTUDIBOHFTPUIFSXJTFTUBUFQMBOGPSEPDVNFOUJOHJNQPSUBOUQSPUPDPMBNFOENFOUT
Not applicable
Support
Sources 5a Indicate sources of inancial or other support for the review 19 675
Sponsor 5b Provide name for the review funder and/or sponsor 19 675
3PMFPGTQPOTPS
funder
5c Describe roles of funder(s), sponsor(s) and/or institution(s), if any, in developing the protocol 19 676
Introduction
3BUJPOBMF 6 Describe the rationale for the review in the context of what is already known 4–6 105–202
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to participants, 
interventions, comparators and outcomes (PICO)
6–7 203–215
Methods
&MJHJCJMJUZDSJUFSJB 8 Specify the study characteristics (eg, PICO, study design, setting, time frame) and report characteristics (eg, 
years considered, language, publication status) to be used as criteria for eligibility for the review
7–8 217–266
Information 
sources
9 Describe all intended information sources (eg, electronic databases, contact with study authors, trial registers 
or other grey literature sources) with planned dates of coverage
8–9 267–282
8 244–246
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such 
that it could be repeated
9 272–273
22 table 3
Study records
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 9 283–287
Selection process 11b State the process that will be used for selecting studies (eg, two independent reviewers) through each phase 
of the review (ie, screening, eligibility and inclusion in meta-analysis)
9 288–302
Data collection 
process
11c Describe planned method of extracting data from reports (eg, piloting forms, done independently, in 
duplicate), any processes for obtaining and conirming data from investigators
10 312–316
Continued
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Section/topic Item # Checklist item
Page no 
reference
Line no. 
reference
Data items 12 List and deine all variables for which data will be sought (eg, PICO items, funding sources), any preplanned 
data assumptions and simpliications
10 317–328
Outcomes and 
prioritisation
13 List and deine all outcomes for which data will be sought, including prioritisation of main and additional 
outcomes, with rationale
7 230–238
20 table 1
3JTLPGCJBT 14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be 
EPOFBUUIFPVUDPNFPSTUVEZMFWFMPSCPUITUBUFIPXUIJTJOGPSNBUJPOXJMMCFVTFEJOEBUBTZOUIFTJT
10–11 338–347
23 table 4
Data
Synthesis 15a Describe criteria under which study data will be quantitatively synthesised 11 349–371
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling 
data and methods of combining data from studies, including any planned exploration of consistency (eg, I2, 
Kendall’s tau)
11–12 373–381
15c Describe any proposed additional analyses (eg, sensitivity or subgroup analyses, meta-regression) 12 388–394
15d If quantitative synthesis is not appropriate, describe the type of summary planned 11 351–352
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (eg, publication bias across studies, selective reporting 
within studies)
12 384–386
Conidence 
in cumulative 
evidence
17 %FTDSJCFIPXUIFTUSFOHUIPGUIFCPEZPGFWJEFODFXJMMCFBTTFTTFE	FH(3"%&
 12 396–399
(3"%&ø(SBEJOHPG3FDPNNFOEBUJPOT"TTFTTNFOU%FWFMPQNFOUBOE&WBMVBUJPO
Table 2 Continued 
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Table 3 Search strategy and terms guide
Search Search terms
Number 
of hits
#1 .FUBCPMJDTZOESPNF03TZOESPNF903JOTVMJOSFTJTUBODFTZOESPNF
#2 )ZQFSUFOTJPO03IJHICMPPEQSFTTVSF
#3 5ZQFEJBCFUFTNFMMJUVT03UZQFEJBCFUFT03EJBCFUFT.FMMJUVT03OPOJOTVMJOEFQFOEFOUEJBCFUFT
03BEVMUPOTFUEJBCFUFT
#4 )VNBO*NNVOPEFýDJFODZ7JSVT03"DRVJSFE*NNVOF%FýDJFODZ4ZOESPNF7JSVT03"*%47JSVT03
)*74FSPOFHBUJWJUJFT034FSPOFHBUJWJUZ)*703)*74FSPQPTJUJWJUJFT034FSPQPTJUJWJUZ)*7
#5 0303"/%
#6 "GSJDBOýMUFS				"OHPMB03#FOJO03#PUTXBOB03A#VSLJOB'BTP03#VSVOEJ03$BNFSPPO03
A$BQF7FSEF03A$FOUSBM"GSJDBO3FQVCMJD03$IBE03$PNPSPT03$POHP03A%FNPDSBUJD
3FQVCMJDPG$POHP03%KJCPVUJ03A&RVBUPSJBM(VJOFB03&SJUSFB03&UIJPQJB03(BCPO03(BNCJB
03(IBOB03(VJOFB03A(VJOFB#JTTBV03A*WPSZ$PBTU03A$PUFE*WPJSF03,FOZB03-FTPUIP
03-JCFSJB03.BEBHBTDBS03.BMBXJ03.BMJ03.BVSJUBOJB03.BVSJUJVT03.P[BNCJRVF03
/BNJCJB03/JHFS03/JHFSJB031SJODJQF033FVOJPO033XBOEB03A4BP5PNF034FOFHBM03
4FZDIFMMFT03A4JFSSB-FPOF034PNBMJB03A4PVUI"GSJDB034VEBO034XB[JMBOE035BO[BOJB
035PHP036HBOEB03A8FTUFSO4BIBSB03;BNCJB03;JNCBCXF03A$FOUSBM"GSJDB03A$FOUSBM
"GSJDBO03A8FTU"GSJDB03A8FTU"GSJDBO03A8FTUFSO"GSJDB03A8FTUFSO"GSJDBO03A&BTU"GSJDB
03A&BTU"GSJDBO03A&BTUFSO"GSJDB03A&BTUFSO"GSJDBO03A4PVUI"GSJDBO03A4PVUIFSO"GSJDB03
A4PVUIFSO"GSJDBO03ATVC4BIBSBO"GSJDB03ATVC4BIBSBO"GSJDBO03ATVC4BIBSBO"GSJDB03ATVC
4BIBSBO"GSJDBO/05AHVJOFBQJH/05AHVJOFBQJHT/05ABTQFSHJMMVTOJHFS




#7 "/%-JNJUTUPJO&OHMJTIBOE'SFODIPOIVNBOT
HIV-infected and HIV-uninfected populations in SSA will 
be sought. The search retrieving will be broad, robust and 
precise using relevant medical subject headings (MeSH)
terms in combination with the African search filter, as 
indicated in table 3.59
1. Electronic search: The following databases will be 
searched: PubMed/Medline, EBSCOhost, Web of 
Science, Google Scholar, Scopus, African Index 
Medicus and Cochrane Database of Systematic 
Reviews for eligible studies.
2. Reference lists search: The reference lists of relevant 
material will be searched to identify additional studies 
of interest.
3. Grey literature search: Authors, experts in the field and 
authors of conference proceedings will be contacted 
through emails for any relevant information, data 
and results. Studies will be excluded after three 
unsuccessful attempts to contact the author.
4. Search management: The records of retrieved 
articles will be managed using EndNote Reference 
Manager X.60 The included and excluded articles at 
each screening stage will be stored as different files. 
Figure 161 indicates the prototype steps for managing 
the records and data for the review.
Study screening and selection
A screening criteria checklist will be developed using 
Google Forms, and tested for reliability and applicability 
to select relevant studies, and will involve three levels: 
title, abstract and full article screening.
1. Title screening: One investigator will independently 
select studies that meet the inclusion criteria by 
screening article titles for significance to the review 
focus and outcome, and duplicate citations will be 
excluded.
2. Abstract screening: Four investigators, two reviewers 
per language, will independently review abstracts of 
the included title-screened articles, being guided by 
the stated inclusion criteria.
3. Full article screening: This will be similar to the 
abstract screening and will further establish the 
eligibility of the identified studies. The first reviewer 
will assess for the articles’ eligibility for meta-analysis, 
general characteristics and outcomes. The second 
reviewer will verify at least 50% of the studies for 
general characteristics information and 100% of 
studies for outcomes data.
4. Screening agreement and disagreement: Screening 
will establish the inter-rater reliability using Cohen’s 
kappa coefficient, κ, which is a robust statistic used for 
inter-rater reliability testing,62 63 and any disagreement 
will be resolved through consultation of the study 
coordinator, if necessary. Authors will be contacted 
if there are missing information and data from the 
published articles that are relevant to the study and 
for further reported result clarity where needed. The 
reasons for exclusion at all stages will be documented.
Data extraction
A Google Form will be designed, pretested and stan-
dardised to extract data from the reviewed and included 
studies. The data extraction and entry will also be 
conducted by two reviewers to establish an inter-rater reli-
ability and avoid data entering errors,63 with disagreement 
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Figure 1 Search management low chart for review.
resolved by the study coordinator. The following data 
items will be extracted:
1. Publication details: author(s) name, year of 
publication, year(s) of study, language, publication 
status.
2. Study characteristics and settings: rural or urban, 
study site, hospital or community/population-based 
country settings, study design, sample size, length of 
study duration of follow-up, source of funding, ethical 
approval.
3. Study participant’s characteristics: sex proportion, 
mean age, HIV status, participants’ number and 
proportion for single studies with multiple outcomes 
and/or population subgroups.
4. Study outcome: Mets, diabetes and hypertension, 
comorbid diabetes and hypertension.
5. Study target population: HIV-positive and/or HIV-
negative study participants, number and proportion 
of participants with or comorbid study outcome (CI, 
p values).
Quality and risk of bias assessment
The quality assessment will be conducted by two 
reviewers using the Effective Public Health Practice 
Project/McMaster Evidence Review and Synthesis Centre 
Tool: Quality Assessment Tool for Quantitative Studies 
(see online supplementary appendix 1).64 The tool was 
selected due to its use of summary scoring to determine 
the quality of studies, ranging from strong, moderate to 
weak, and its ability to assess all types of quantitative study 
methods. This is important, as scale or checklist tools are 
more likely to include criteria that do not directly relate 
to internal validity, resulting in unreliable validity assess-
ment.65 The summary scores for all the included studies 
will be documented and reported in the final review. 
The study’s risk of bias will be performed using the risk 
of bias tool for prevalence studies by Hoy et al66 and the 
Cochrane guidelines available in Review Manager V.5.3 
(http:// tech. cochrane. org/ revman) (table 4). The 
quality and risk of bias assessment will be presented as 
part of the table of characteristics of the included studies. 
The inter-rater agreement will be calculated using the 
proportion of agreement and kappa statistics. The 
minimum sample size for included studies will be calcu-
lated to determine a good precision estimate, using the 
pooled estimate of study outcomes prevalence among 
PLHIV and HIV-negative populations. This calculation 
will use the Clopper-Pearson CI formula,67 and a study 
with good precision for this meta-analysis will be defined 
as one whose sample size is greater than or equal to the 
calculated minimum sample size.
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Table 4 3JTLPGCJBTUPPM	BEBQUFEGSPN)PZet al66 tool for prevalence studies)
Study title:
Name of author(s)
Year of publication
Risk of bias items
Risk of bias level: low 
risk = yes, high risk = no
Score:
yes=0,
no=1
&YUFSOBMWBMJEJUZ
  1. Was the study target population a close representation of the national population in 
relation to relevant variables, for example, age, sex?
  2. Was the sampling frame a true or close representation of the target population?
 8BTTPNFGPSNPGSBOEPNTFMFDUJPOVTFEUPTFMFDUUIFTBNQMF03XBTBDFOTVT
undertaken?
  4. Was the likelihood of non-participation bias minimal?
Internal validity
  5. Was data collected directly from the participants (as opposed to proxy)?
  6. Were acceptable case deinitions and diagnostic measures of metabolic syndrome, 
diabetes and hypertension used?
  7. Were the study instruments that measured the parameter of interest (eg, prevalence 
of diabetes) shown to have reliability and validity (if necessary)?
  8. Was the same mode of data collection used for all study participants?
  9. Was the length of the shortest prevalence period for the parameter of interest 
appropriate?
  10. Were the numerator(s) and denominator(s) for the calculation of the prevalence of 
metabolic syndrome, diabetes and hypertension appropriate?
Presentation of summary on the overall risk of study bias.
The total score ranged from 0 to 9, with the overall score categorised as follows:
ø-PXSJTLPGCJBTøPSNPSFAZFTBOTXFSTøGVSUIFSSFTFBSDIJTWFSZVOMJLFMZUPDIBOHFPVSDPOýEFODFJOUIFFTUJNBUF
ø.PEFSBUFSJTLPGCJBToAZFTBOTXFSTGVSUIFSSFTFBSDIJTMJLFMZUPIBWFBOJNQPSUBOUJNQBDUPOPVSDPOýEFODFBOENBZDIBOHFJOUIF
estimate.
ø)JHISJTLPGCJBTøPSGFXFSAZFTBOTXFSTGVSUIFSSFTFBSDIJTWFSZMJLFMZUPIBWFBOJNQPSUBOUJNQBDUPOPVSDPOýEFODFBOEMJLFMZDIBOHF
the estimate.
Data synthesis and analysis
The data will be systematically described, analysed and 
summarised to answer the four research questions, and 
the data will be narratively synthesised if meta-analysis 
cannot be performed.
Data analysis
The prevalence results of Mets (and its subcomponents), 
discrete and/or comorbid diabetes and hypertension 
will be stratified and compared by HIV status to estab-
lish any significant difference. As some definitions of 
Mets include diabetes and blood pressure as criteria, 
the prevalence of subcriteria in studies that assessed 
Mets across HIV-positive and HIV-negative populations 
will be included as a secondary objective. The preva-
lence estimate will be presented by country, geographical 
region and HIV status. Furthermore, given the interna-
tional changes in the definition of diabetes, hypertension 
and Mets, the analysis will also be stratified by the period 
of definition used in the included/eligible studies. This 
study-specific prevalence estimates will be pooled using 
the random-effects meta-analysis model to present the 
mean of the distribution of effects between HIV-infected 
and HIV-negative populations.68 The variance for the 
random meta-analysis estimate will be computed using 
the updated DerSimonian and Laird variance estimator 
method.69 The random-effects model will be used in antic-
ipation of substantial variation in Mets prevalence and on 
the different outcome definitions across the included 
studies/period. To minimise the effect of extreme 
prevalence on the overall estimates, single arcsine trans-
formation will be performed on the raw prevalence before 
pooling the data.70 CIs at 95% will be calculated for all 
reported study outcome prevalence measures using the 
Clopper-Pearson method.67
Heterogeneity
The statistical heterogeneity in the meta-analysis will 
be assessed using the I2 statistic,71 and if the I2 value 
is greater than 50%, it will be regarded as substantial 
heterogeneity. Forest plots and the overall random-ef-
fects pooled estimate will be generated to display 
prevalence with the corresponding CI for each study. If 
asymmetry is present based on visual assessment, explor-
atory analyses will be performed to investigate and adjust 
this using trim and/or fill analysis. The prevalence of 
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the study outcomes between mean/median age and 
gender will be estimated. Meta-regression analysis will 
be explored among HIV-infected participants who are 
on antiretroviral treatment and are treatment-naïve, if 
adequate data are found.
Publication bias
If there are ≥10 studies in the meta-analysis, publication 
bias will be further investigated using funnel plots and 
Egger’s test,72 the data being analysed using Stata V.13.0.
Sensitivity analysis
A sensitivity analysis to assess the robustness of the individual 
study designs and data set of the observed outcomes to the 
analysis assumptions will also be undertaken to further 
reduce the risk of bias assessment. The primary analysis 
will be repeated with altered extracted data sets and statis-
tical methods to determine any changes in the combined 
outcome estimate effect.73 The data set and statistical model 
for the statistical analysis will be determined during the 
review process and reported in the final review.
Strength of evidence assessment
The quality and strength of evidence extracted from the 
included and analysed studies will be assessed using the 
Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) approach. The GRADEpro 
software will be used to assist in grading the evidence and 
presenting the summary of findings in the review and 
meta-analysis.74
Review reporting and dissemination
The proposed systematic review and meta-analysis will be 
guided by the PRISMA guidelines.58 The final report and 
completed PRISMA checklist will be published as a scien-
tific article in a peer-reviewed journal. In addition, the 
review findings will be presented at conferences and/or 
to relevant health agencies.
Potential amendments
While there are no planned amendments for this 
protocol, if any substantial amendments arise during the 
review itself, these will be documented and reported in 
the published findings.
Ethical consideration
As the present review and meta-analysis study will use 
aggregated published data and information for analysis, 
no ethical approval will be required.
CONCLUSION
This systematic review and meta-analysis will attempt to 
identify the distribution of Mets, diabetes and hyperten-
sion and their common related comorbidities between 
PLHIV and HIV-negative general populations across 
SSA. The rigorous methodology proposed for this review 
will ensure a robust knowledge synthesis and provide 
evidence-based knowledge of the prevalence of the 
study outcomes for stakeholders, researchers and policy 
makers. This will assist with indicating the research gaps 
and priorities for Mets, diabetes and hypertension in 
the whole of Africa.
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